NIBRT announces collaboration to improve downstream bioprocessing bottlenecks

A collaboration between the NIBRT and Avantor aims to address issues faced in downstream bioprocessing during buffer preparation for mAbs.

Antibody near cells

The National Institute of Bioprocessing Research and Training (NIBRT) in Ireland has announced its collaboration with Avantor to address downstream bioprocessing bottlenecks in buffer preparation when producing monoclonal antibodies (mAbs).

According to the NIBRT, the new in-line dilution systems from this partnership will complement the organisation’s bioprocessing capabilities.

Buffer management can help to advance bioprocessing production by reducing downstream bottlenecks and costs”

Dominic Carolan, NIBRT Chief Executive Officer, stated: “This collaboration further advances our mission of providing a world-class research and training centre of excellence. Technicians and professionals will benefit from access to the latest bioprocessing production knowledge, technology and innovation in buffer management.”

Buffers are a critical component when producing and purifying mAbs and are extensively used in upstream and downstream production. Recent activities in upstream optimisation have resulted in increasing production yields, which has now placed pressure on downstream purification resources. In addition, demand for multi-product facilities has placed a strain on capacity for traditional buffer preparation.

Dr Ger Brophy, Executive Vice President, Biopharma Production for Avantor, said: “Demand for therapeutic biologics is increasing and this will require increased manufacturing productivity. At the same time, there is significant pressure on the biopharma industry to reduce overall costs while ensuring that safety and quality are not compromised. This has resulted in initiatives to improve efficiency and increase flexibility in bioprocessing facilities. Buffer management is a key process step which is prime for optimisation.” 

Buffer management can help to advance bioprocessing production by reducing downstream bottlenecks and costs. The NIBRT says that this collaboration will provide industry-leading buffer management training to help mitigate downstream challenges, which will help new therapies to reach patients faster and more cost effectively.

“We’re proud to be collaborating with NIBRT to move science forward through innovation, training and hands-on experience with the latest technology,” added Dr Brophy.